Cancer Research AACR Conference on Molecular Diagnostics - 2008 AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boulares, A. H.
Right arrow Articles by Smulson, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boulares, A. H.
Right arrow Articles by Smulson, M. E.
[Cancer Research 62, 4439-4444, August 1, 2002]
© 2002 American Association for Cancer Research

Molecular Biology and Genetics

The Poly(ADP-ribose) Polymerase-1-regulated Endonuclease DNAS1L3 Is Required for Etoposide-induced Internucleosomal DNA Fragmentation and Increases Etoposide Cytotoxicity in Transfected Osteosarcoma Cells1

A. Hamid Boulares2, Anna J. Zoltoski, Zaki A. Sherif, Alexander G. Yakovlev and Mark E. Smulson

Departments of Biochemistry and Molecular Biology [A. H. B., A. J. Z., Z. A. S., M. E. S.] and Neuroscience [A. G. Y.], Georgetown University School of Medicine, Washington, DC 20007


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The cytotoxic effect of the chemotherapeutic drug etoposide (VP-16) is thought to result from itsability to induce DNA damage and thereby to trigger apoptosis. Internucleosomal DNA fragmentation occurs late during apoptosis in many cell types. However, whereas human osteosarcoma cells undergo internucleosomal DNA fragmentation during staurosporine-induced apoptosis, they fail to do so in response to VP-16. Recently, we showed that these cells also do not express the poly(ADP-ribosyl)ation-regulated Ca2+- and Mg2+-dependent endonuclease DNAS1L3. The possibility that this deficiency underlies the failure of these cells to undergo internucleosomal DNA fragmentation in response to VP-16 was investigated. The proteolytic processing and consequent activation of procaspase-3, cleavage of the inhibitory subunit of DNA fragmentation factor, and the degradation of DNA into 50-kb fragments occurred similarly in osteosarcoma cells exposed to either staurosporine or VP-16. However, the additional processing of the 50-kb DNA fragments to oligonucleosomal fragments was not apparent in the VP-16-treated cells. Ectopic expression of DNAS1L3 conferred on osteosarcoma cells the ability to undergo VP-16-induced internucleosomal DNA fragmentation. Furthermore, expression of DNAS1L3 markedly potentiated the cytotoxic effect of VP-16 in these cells. Both DNAS1L3-mediated and staurosporine-induced internucleosomal DNA fragmentation were Ca2+ dependent, but only the DNAS1L3-mediated DNA cleavage was blocked by expression of a caspase-3-resistant mutant of poly(ADP-ribose) polymerase-1. The present work results suggest a direct relation between the activity of a chemotherapeutic drug (VP-16) and a specific endonuclease (DNAS1L3). They also indicate that internucleosomal DNA fragmentation plays an active role in apoptosis and that the failure of cancer cells to undergo such DNA degradation may contribute to the development of resistance to chemotherapeutic drugs.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Successful drug treatment in human cancers requires an adequate therapeutic indicator reflecting the specific molecular mechanisms of action of the treatment on target cells. These effects may be enzymatic or structural in nature. Determining the specific factors that are involved in the complex events of cell killing by chemotherapeutic drugs not only provides an understanding of the mechanism by which cancer cells are killed but may also provide important insight for developing new targets and strategies in the treatment of cancer.

Defective induction of apoptosis is implicated in the progression of malignancy and the development of resistance to chemotherapeutic drugs in many types of cancer (1) . The chemotherapeutic agent VP-16,3 an epipodophyllotoxin that inhibits DNA topoisomerase II, is thought to induce apoptosis as a consequence of the persistent DNA damage that results from the inability of the inhibited enzyme to mediate the religation of single- and double-strand breaks (2) . Apoptosis is characterized by major changes in cell morphology, including chromatin condensation, membrane blebbing, nuclear breakdown, and the formation of membrane-associated apoptotic bodies. At the molecular level, these changes are accompanied by the cleavage of many housekeeping proteins, including PARP-1 and lamins, and ultimately by internucleosomal DNA fragmentation. Regardless of the stimulus, the initiation and execution of apoptosis are mediated by members of the caspase family of aspartate-specific cysteine proteases.

Internucleosomal DNA fragmentation is a terminal step in disposal of the genome in cells undergoing apoptosis. Defective DNA fragmentation has been associated with an increased resistance of cells to apoptosis (3, 4, 5) . The mechanism of DNA fragmentation in apoptotic cells is poorly understood, although several endonucleases have been implicated in this process (6 , 7) . The candidate endonucleases identified to date differ in characteristics such as Ca2+ and Mg2+ dependence, optimal pH, tissue distribution, and requirement for caspase-3 (7, 8, 9, 10) . DFF, also known as caspase-activated DNase, has been suggested to play a major role both in the early transient appearance of DNA strand breaks and in internucleosomal DNA fragmentation during apoptosis (7 , 11, 12, 13) . DFF is composed of two subunits of Mr 40,000 and 45,000, termed DFF40 (caspase-activated DNase) and DFF45 inhibitor of caspase-activated DNase (ICAD), respectively (5 , 11, 12, 13) . The endonuclease activity of this enzyme, which is intrinsic to DFF40, is induced on cleavage of DFF45 by caspase-3.

We have recently cloned and characterized DNAS1L3 (14 , 15) , which is the human homologue of a bovine chromatin-bound and Ca2+- and Mg2+-dependent endonuclease (16) , and also contributes to internucleosomal DNA degradation during apoptosis (15 , 17) . The activity of DNAS1L3 (15 , 17) , like that of the bovine endonuclease (16 , 18) , is reversibly inhibited by poly(ADP-ribosyl)ation. We have also shown that human osteosarcoma cells do not express DNAS1L3, as assessed by reverse transcription and PCR analysis, and that these cells fail to undergo internucleosomal DNA fragmentation after exposure to VP-16 (17) . Incubation of purified rat cerebella nuclei with purified DNAS1L3 in the presence of Ca2+ and Mg2+ results in cleavage of DNA in a pattern identical to that observed in apoptotic cells (14) . We showed recently, in an in vitro study, that the inhibition of DNAS1L3 endonuclease activity by PARP-1 is blocked when PARP-1 is neutralized by active recombinant caspase-3 (17) . However, the osteosarcoma cells do exhibit internucleosomal DNA fragmentation in response to staurosporine (19) or during confluency-triggered spontaneous apoptosis (20 , 21) .

We have now investigated this difference between the abilities of VP-16 and staurosporine to induce internucleosomal DNA fragmentation in osteosarcoma cells, specifically exploring the possibility that DNAS1L3 contributes to VP-16 cytotoxicity. In addition, we examined the roles of PARP-1 and Ca2+ in the regulation of DNAS1L3-mediated and staurosporine-induced DNA fragmentation.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture, Transfection, and Induction of Apoptosis.
Human osteosarcoma cells (143.98.2; ATCC CRL 11226; Refs. 20 , 22 ) were maintained in DMEM supplemented with 10% fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 µg/ml). Cells were transfected with vectors encoding human DNAS1L3 (14) or a caspase-3-resistant human mut-PARP-1 (19) with the use of Mirus TransIT-100 reagent (Panvera, Madison, WI). Both DNAS1L3 and mut-PARP-1 cDNAs were positioned immediately downstream of the coding sequence for six histidine residues and the FLAG epitope, and were cloned in pcDNA3.1 and pCR3.1 mammalian expression vectors (Invitrogen, Carlsbad, CA), respectively. Expression of DNAS1L3 or mut-PARP-1 was tested by immunoblot analysis with antibodies to the FLAG epitope as described below. Apoptosis was induced by exposing cells to 70 µM VP-16 or 1 µM staurosporine (Sigma) for 24 or 36 h at 37°C.

Analysis of Internucleosomal DNA Fragmentation.
Genomic DNA was isolated from cells as described previously (19) , subjected to electrophoresis through a 1.5% agarose gel in Tris-borate EDTA buffer, and stained with ethidium bromide.

Measurement of Cell Viability.
After treatment with VP-16 or staurosporine, cell viability was assessed essentially as described (19) .

Immunoblot and Immunoprecipitation Analyses.
Cells were washed with an ice-cold phosphate buffer saline and then lysed as described (19) . A portion (30 µg of protein) of each lysate was fractionated by SDS-PAGE on a 4–20% gradient gel. Alternatively, recombinant DNAS1L3 was precipitated from cell lysates (250 µg of protein) with Ni-NTA magnetic beads (Qiagen, Valencia, CA), and the precipitates were subjected to electrophoresis. Separated proteins were transferred to a nitrocellulose filter, which, after staining with Ponceau S to confirm equal loading and transfer of samples, was probed with antibodies to FLAG (Santa Cruz Biotechnology, Santa Cruz, CA), to caspase-3 (Santa Cruz Biotechnology), to PARP-1 (PharMingen, San Diego, CA), to PAR (Alexis Biochemicals, San Diego, CA), or to DFF45 (kindly provided by X. Wang, University of Texas, Southwestern Medical Center, Dallas, TX). Immune complexes were detected with appropriate secondary antibodies and chemiluminescence reagents (Pierce, Rockford, IL).

Immunofluorescence Microscopy.
Cells were fixed, permeabilized, and stained with a rabbit antibody to FLAG to PAR essentially as described (19) . They were then examined with a Nikon fluorescence microscope.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Staurosporine but not VP-16 Induces Internucleosomal DNA Fragmentation in Osteosarcoma Cells.
Osteosarcoma cells were incubated in the absence or presence of either 1 µM staurosporine or 70 µM VP-16 for 36 h, after which genomic DNA was extracted and analyzed by agarose gel electrophoresis. Whereas staurosporine induced marked internucleosomal DNA fragmentation, such cleavage of DNA was not detected in the cells treated with VP-16 (Fig. 1A)Citation . Assessment of cell viability by calcein-AM staining revealed that both drugs exhibited substantial cytotoxicity in the osteosarcoma cells, with the effect of staurosporine being slightly greater than that of VP-16 (Fig. 1B)Citation . Thus, internucleosomal DNA fragmentation does not appear to be absolutely required for the cytotoxic effect of VP-16. These results also suggest that the staurosporine-induced endonuclease activity is insensitive to VP-16 and, therefore, independent of inhibition of topoisomerase II.



View larger version (34K):
[in this window]
[in a new window]
  		Fig. 1. Effects of VP-16 and staurosporine on internucleosomal DNA fragmentation (A) and viability (B) in human osteosarcoma cells. A, cells were incubated for 36 h in the absence (Con) or presence of 70 µM VP-16 or 1 µM staurosporine (Stauro), after which genomic DNA was isolated and examined by agarose gel electrophoresis and ethidium bromide staining. B, cells were treated as in A, and cell viability was then assessed by calcein-AM staining. Cell viability is expressed as a percentage of the control value, and data are means of quadruplicate determinations from a representative experiment; bars, ±SD.

 
Caspase-3 Activation, Cleavage of DFF45, and Degradation of DNA into 50-kb Fragments Are Insufficient for Induction of Internucleosomal DNA Fragmentation in VP-16-treated Osteosarcoma Cells.
Activation of caspase-3 and the consequent cleavage of DFF45 are necessary for internucleosomal DNA fragmentation in many cell lines (11 , 23 , 24) . Therefore, we examined whether the lack of internucleosomal DNA fragmentation in VP-16-treated osteosarcoma cells was because of a defect in the activation of caspase-3 or the cleavage of DFF45.

Cells were incubated for 24 h in the absence or presence of staurosporine or VP-16, after which cell extracts were prepared and subjected to immunoblot analysis with antibodies to caspase-3 that recognize both the full-length precursor as well as its Mr 20,000 and Mr 17,000 active fragments. Both drugs induced cleavage of procaspase-3 in a manner indicative of its activation (Fig. 2A)Citation . To confirm that the processed caspase-3 was catalytically active, we examined the status of PARP-1, a caspase-3 substrate, by immunoblot analysis of the same cell extracts with antibodies that recognize both full-length PARP-1 and its Mr 89,000 cleavage product. Both staurosporine and VP-16 induced the cleavage of PARP-1 (Fig. 2A)Citation , verifying that the caspase-3 fragments were catalytically active and that differential activation of this enzyme does not underlie the differential induction of internucleosomal DNA fragmentation by the two drugs.



View larger version (48K):
[in this window]
[in a new window]
  		Fig. 2. Activation of caspase-3 (A), cleavage of DFF45 (B), and degradation of DNA into 50-kb fragments (C) during VP-16-induced apoptosis in human osteosarcoma cells. A, cells were incubated for 24 h in the absence or presence of 70 µM VP-16 or 1 µM staurosporine, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies either to human caspase-3 (top panel) or to human PARP-1 (bottom panel). B, lysates prepared from cells treated as in A were also subjected to immunoblot analysis with antibodies to human DFF45; the bottom panel represents a longer exposure of the filter shown in the top panel. C, DNA was isolated from control cells or from cells treated with VP-16 or staurosporine for 24 or 36 h and was subjected to transverse alternating-field electrophoresis.

 
We next examined the proteolytic processing of DFF45 in osteosarcoma cells treated with VP-16 or staurosporine. Both drugs induced substantial cleavage of DFF45 into the Mr 32,000 and Mr 11,000 fragments characteristic of apoptotic cells (Fig. 2B)Citation . Thus, neither impaired activation of caspase-3 nor defective cleavage of DFF45 appears to underlie the failure of osteosarcoma cells to undergo internucleosomal DNA fragmentation during VP-16-induced apoptosis.

We (5 , 25) and others (26) have shown that either depletion of DFF40 as a result of DFF45 gene disruption or inhibition of endogenous DFF40 by expression of a caspase-3-resistant DFF45 mutant (27) prevents the cleavage of genomic DNA into 50-kb fragments in response to inducers of apoptosis. We next examined whether the failure of osteosarcoma cells to undergo internucleosomal DNA fragmentation in response to VP-16 was associated with impaired generation of such large DNA fragments. Cells were treated with either staurosporine or VP-16 for 24 or 36 h, after which DNA was isolated and subjected to transverse alternating-field electrophoresis as described (19) . The two drugs induced the generation of 50-kb DNA fragments to similar extents (Fig. 2C)Citation . however, of potential importance, whereas the abundance of these DNA fragments decreased with time of exposure of cells to staurosporine, it remained essentially unchanged during VP-16 treatment. These results suggest that VP-16-treated osteosarcoma cells fail to process the 50-kb DNA fragments into oligonucleosomal fragments. Thus, osteosarcoma cells appear to lack an endonuclease activity that mediates the additional processing of 50-kb DNA fragments in response to VP-16.

VP-16 Induces Internucleosomal DNA Fragmentation in Osteosarcoma Cells Expressing Recombinant DNAS1L3.
We have shown previously that human osteosarcoma cells, unlike various other cell lines such as U-937 human monocytes, do not express DNAS1L3, as assessed by reverse transcription and PCR analysis with primers specific for human DNAS1L3 cDNA (17) . Therefore, we examined the effect of ectopic expression of DNAS1L3 in these cells on their ability to undergo internucleosomal DNA fragmentation in response to VP-16. Osteosarcoma cells were stably transfected with an expression vector encoding DNAS1L3 with a His6-FLAG tag. The expression and nuclear localization of the recombinant DNAS1L3 were confirmed by immunofluorescence analysis (Fig. 3A)Citation and immunoblot analysis (data not shown) with antibodies to the FLAG epitope. Exposure of the transfected cells to VP-16 resulted in marked internucleosomal DNA fragmentation (Fig. 3B)Citation , and this effect was blocked by inclusion in the culture medium of BAPTA, a cell-permeable Ca2+ chelator. These results suggest that the endonuclease activity of DNAS1L3 mediated internucleosomal DNA fragmentation in the transfected cells and that this activity was dependent on Ca2+. BAPTA also blocked staurosporine-induced internucleosomal DNA fragmentation in osteosarcoma cells transfected with empty vector (Fig. 3B)Citation , indicating that this drug also activates a Ca2+-dependent endonuclease.



View larger version (34K):
[in this window]
[in a new window]
  		Fig. 3. Effects of ectopic expression of DNAS1L3 on the ability of VP-16 to induce internucleosomal DNA fragmentation and on the cytotoxicity of this drug in human osteosarcoma cells. A, expression of recombinant DNAS1L3 in osteosarcoma cells. Cells were transfected either with an expression vector encoding DNAS1L3 with a His6-FLAG tag or with the corresponding empty vector. The expression and subcellular localization of recombinant DNAS1L3 were then examined by immunofluorescence analysis with antibodies to FLAG and rhodamine-conjugated secondary antibodies (top panels). Cell nuclei were also stained by Hoechst 33258 (bottom panels). B, effect of DNAS1L3 expression on DNA integrity in VP-16-treated osteosarcoma cells and effect of BAPTA on VP-16 or staurosporine-induced internucleosomal DNA fragmentation. Cells transfected with the DNAS1L3 expression vector were incubated for 24 h in the absence or presence of 70 µM VP-16 or 20 µM BAPTA. Osteosarcoma cells transfected with empty vector were incubated for 24 h in the absence or presence of 1 µM staurosporine or 20 µM BAPTA. Genomic DNA was then isolated and analyzed by agarose gel electrophoresis and ethidium bromide staining. C, effect of DNAS1L3 expression on VP-16-induced cell death. Cells expressing DNAS1L3 ({circ}) or those transfected with the empty vector ({blacksquare}) were incubated for the indicated times in the presence of 70 µM VP-16, after which cell viability was assessed by staining with calcein-AM. Data are expressed as a percentage of the viability of the corresponding untreated cells and are means of quadruplicate determinations from a representative experiment; bars, ±SD.

 
We next determined the effect of expression of DNAS1L3 on the sensitivity of osteosarcoma cells to VP-16 cytotoxicity. Expression of DNAS1L3 potentiated the cytotoxic effect of VP-16, compared with that apparent in cells transfected with the empty vector (Fig. 3C)Citation , suggesting that this enzyme is a determinant of the sensitivity of cells to VP-16. These results also indicate that internucleosomal DNA fragmentation is not merely an end point of apoptosis, but rather contributes to the overall process of cell death, in VP-16-treated osteosarcoma cells.

Expression of a Caspase-3-resistant Mut-PARP-1 Inhibits VP16-induced, DNAS1L3-mediated Internucleosomal DNA Fragmentation in Osteosarcoma Cells.
We have shown recently that the endonuclease activity of DNAS1L3 is negatively regulated by PARP-1-mediated poly(ADP-ribosyl)ation both in vitro and in vivo (15 , 17) . Therefore, we investigated whether PARP-1 differentially modulates internucleosomal DNA fragmentation mediated by DNAS1L3 in response to VP-16 and that induced by staurosporine by transfecting osteosarcoma cells with vectors encoding DNAS1L3 and a caspase-3-resistant mut-PARP-1, the latter of which was also tagged with the His6-FLAG sequence. Immunoblot analysis with antibodies to FLAG confirmed the expression of the recombinant proteins in the transfected cells (data not shown). The transfected cells were treated with staurosporine or VP-16 for 24 h, after which DNA was isolated and subjected to agarose gel electrophoresis. Whereas expression of caspase-3-resistant mut-PARP-1 prevented the induction of internucleosomal DNA fragmentation by VP-16 in cells expressing DNAS1L3 (Fig. 4A)Citation , it did not affect that induced by staurosporine in cells not expressing DNAS1L3 (Fig. 4B)Citation . These results suggest that PARP-1 regulates VP-16-induced, DNAS1L3-mediated internucleosomal DNA fragmentation but not such DNA fragmentation induced by staurosporine, additionally supporting the notion that the endonuclease activated by staurosporine is distinct from DNAS1L3. Moreover, cleavage of PARP-1 and concomitant cessation of poly(ADP-ribosyl)ation appears to be necessary for DNAS1L3-mediated internucleosomal degradation of DNA, consistent with our previous in vitro and in vivo observations (17) .



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 4. Effects of a caspase-3-resistant mut-PARP-1 on internucleosomal DNA fragmentation either mediated by DNAS1L3 in response to VP-16 or induced by staurosporine in human osteosarcoma cells. A, effect of mut-PARP-1 expression on DNAS1L3-mediated internucleosomal DNA fragmentation in VP-16-treated cells. Cells expressing recombinant DNAS1L3 or mut-PARP-1, or both proteins, were incubated for 24 h in the absence or presence of 70 µM VP-16, after which internucleosomal DNA fragmentation was analyzed by electrophoresis. B, effect of mut-PARP-1 expression on staurosporine-induced internucleosomal DNA fragmentation. Cells expressing mut-PARP-1 or transfected with the corresponding empty vector were incubated in the absence or presence of 1 µM staurosporine for 24 h, after which internucleosomal DNA fragmentation was analyzed as in A. C, effects of VP-16 and mut-PARP-1 expression on poly(ADP-ribosyl)ation of recombinant DNAS1L3 in osteosarcoma cells. Cells expressing DNAS1L3 either alone or together with mut-PARP-1 were incubated for 12 h in the absence of presence of 70 µM VP-16, after which the His6-FLAG-tagged recombinant proteins were precipitated from cell lysates and subjected to immunoblot analysis with antibodies to PAR.

 
To confirm that DNAS1L3-mediated internucleosomal DNA fragmentation in response to VP-16 was inhibited as a consequence DNAS1L3 poly(ADP-ribosyl)ation, we precipitated DNAS1L3 from VP-16-treated osteosarcoma cells expressing this endonuclease in the absence or presence of mut-PARP-1. The precipitates were then subjected to immunoblot analysis with antibodies to PAR. VP-16 induced a moderate increase in the extent of poly(ADP-ribosyl)ation of DNAS1L3 in cells expressing the endonuclease alone, but this effect was markedly potentiated by coexpression of the mut-PARP-1 (Fig. 4C)Citation . Thus, these results confirm the regulation of DNAS1L3 by poly(ADP-ribosyl)ation and are consistent with the DNA fragmentation data for the transfected cells. They additionally suggest that removal of PAR moieties attached to DNAS1L3 by the action of PAR glycohydrolase is required for induction of the endonuclease activity of this protein in cells undergoing VP-16-induced apoptosis.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We have shown that expression of DNAS1L3 is required for VP-16-induced internucleosomal DNA fragmentation in human osteosarcoma cells, thereby identifying a specific relation between a proapoptotic chemotherapeutic drug and an apoptotic endonuclease. Ectopic expression of DNAS1L3 also increased the rate of VP-16-induced apoptosis in these cells, suggesting that the resistance of certain cancer cells to VP-16 might result from DNAS1L3 deficiency. Furthermore, our data show that osteosarcoma cells fail to undergo internucleosomal DNA fragmentation during VP-16-induced apoptosis despite their harboring an endonuclease capable of mediating such DNA cleavage in response to staurosporine, and despite their exhibiting such apoptotic events as caspase-3 activation, cleavage of PARP-1 and DFF45, and the consequent degradation of genomic DNA into 50-kb fragments in response to VP-16. Failure to undergo internucleosomal DNA fragmentation was also observed in other cell lines such as the cervical carcinoma cell line, HeLa, as well as the non-Hodgkin’s lymphoma cell line, Daudi.4

The fact that osteosarcoma cells undergo internucleosomal DNA fragmentation during staurosporine-induced apoptosis indicates the presence of an endonuclease activity that is capable of catalyzing this reaction but which is not responsive to VP-16. These cells gained the ability to degrade their DNA into oligonucleosomal fragments in response to VP-16 when transfected with an expression vector encoding DNAS1L3, suggesting that this enzyme is required for VP-16-induced internucleosomal DNA fragmentation.

The reason that VP-16 activates DNAS1L3 but not the endonuclease activated by staurosporine is unclear. Clearly, the two drugs act in different fashions. Staurosporine is a bacterial alkaloid that was initially described as an inhibitor of protein kinase C (28) but has subsequently been shown to inhibit many additional protein kinases (29 , 30) . Moreover, staurosporine induces apoptosis in virtually all of the cell types examined to date (19 , 31, 32, 33, 34) . Staurosporine-induced cell death is associated with a rapid and prolonged increase in the intracellular Ca2+ concentration and accumulation of reactive oxygen species (35 , 36) . VP-16 is a potent inhibitor of topoisomerase II; it stabilizes a complex between the enzyme and DNA, and thereby induces DNA strand breakage (2) . In contrast to that elicited by staurosporine, cell death induced by VP-16 is not associated with the intracellular generation of reactive oxygen species (37) , suggesting that oxidative stress might contribute to the induction of internucleosomal DNA fragmentation by staurosporine. The generation of reactive oxygen species has been associated with the release of Ca2+ from intracellular stores (38 , 39) , which results in the activation of Ca2+-dependent enzymes such as certain endonucleases. However, intracellular Ca2+ release is not likely a factor in the differential induction of internucleosomal DNA fragmentation by staurosporine or VP-16 in osteosarcoma cells or in the preferential activation of DNAS1L3 by VP-16. Both internucleosomal DNA fragmentation mediated by recombinant DNAS1L3 in response to VP-16 and that induced by staurosporine in osteosarcoma cells were dependent on Ca2+, given that both were inhibited by BAPTA. Moreover, these results suggest that Ca2+ was, in fact, released from intracellular stores in cells treated with either staurosporine or VP-16, consistent with previous data showing that both drugs induce intracellular Ca2+ release in other cell types (36 , 40, 41, 42) . However, the release of Ca2+ induced by VP-16 likely occurs independently of the generation of reactive oxygen species.

A characteristic of DNAS1L3 not described for other endonucleases is its regulation by poly(ADP-ribosyl)ation. Although VP-16 induces DNA strand breakage by inhibiting topoisomerase II, the strand breaks are not accessible to PARP-1 because they remain associated with topoisomerase II (43) . Furthermore, topoisomerase II is a significant substrate of PARP-1 and is inhibited in the poly(ADP-ribosyl)ated state (44) . However, the strand breaks therefore cannot likely contribute either to the activation of PARP-1, which is triggered by binding of the enzyme to the ends of DNA strands or to the consequent inhibition of DNAS1L3. The staurosporine-specific induction of endonuclease activity in osteosarcoma cells likely requires factors that are not targeted by VP-16.

Activation of caspase-3 has been shown to be required for internucleosomal DNA fragmentation (23 , 45) . However, it is unlikely that caspase-3 activation is a factor that underlies the differential induction of internucleosomal DNA fragmentation by staurosporine or VP-16 in osteosarcoma cells, given that activation of this protease (as evidenced both by cleavage of the proenzyme and by proteolysis of its substrates, PARP-1 and DFF45) was detected in cells treated with either drug. Clearly, additional experimentation is required to fully delineate the mechanisms responsible for the difference in inducing internucleosomal DNA fragmentation between the two drugs in osteosarcoma cells.

The activation of DFF, which results from the cleavage of DFF45, also did not appear to differ between osteosarcoma cells exposed to VP-16 and those exposed to staurosporine. We and others have shown recently that expression and cleavage of DFF45 are required for the processing of DNA into both 50-kb and oligonucleosomal fragments (5 , 25, 26, 27) . The generation of 50-kb DNA fragments was observed in osteosarcoma cells treated with either staurosporine or VP-16. However, whereas in staurosporine-treated cells the 50-kb DNA fragments were processed additionally with time into oligonucleosomal fragments, those in VP-16-treated cells remained unchanged. These results suggest that DFF may contribute to the generation of 50-kb DNA fragments but is not responsible for internucleosomal DNA cleavage in osteosarcoma cells.

The novel observation concerning the molecular mechanism of an anticancer drug is the fact that ectopic expression of DNAS1L3 increased the sensitivity of osteosarcoma cells to VP-16-induced cell death. This effect might be attributable to an increased generation of DNA breaks in the transfected cells. These additional DNA breaks may enhance nuclear poly(ADP-ribosyl)ation and thereby result in an increased rate or extent of NAD depletion, which culminates in collapse of the mitochondrial membrane potential and release of cytochrome c. Resistance of cancer cells to chemotherapeutic drugs has been associated with altered drug metabolism (which has been attributed to increased expression of the P-glycoprotein encoded by the MDR gene), with increased redox detoxifying action of glutathione, with increased hepatic cytochrome P450 activity, and with mutation of topoisomerase II. Resistance of cells to apoptosis has been attributed to increased expression either of antiapoptotic factors, such as members of the Bcl-2 family of proteins, or of proliferative factors, such as phosphoinositide 3'-kinase and the protein kinase Akt (1 , 46) . Our results now suggest that loss of expression or inactivation of endonucleases also might contribute to reduced sensitivity of cells to drug-induced apoptosis. Internucleosomal DNA fragmentation has been considered merely as an end point of apoptosis, as a means to dispose of genomic DNA. However, our present data suggest that endonucleases such as DNAS1L3 might also play an active role in apoptotic cell death. The demonstration that DNAS1L3 is directly associated with VP-16-induced cell death may facilitate the development of new approaches to anticancer therapy.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by National Cancer Institute Grants PO1CA-74175 and CA25344 (to M. E. S.), by National Institute of Neurological Disorders and Stroke Grant NS38941 (to A. G. Y.), and by National Cancer Institute Grant CA87554 (to Z. A. S.). Back

2 To whom requests for reprints should be addressed, at Department of Biochemistry and Molecular Biology, Basic Science Building, Room 347, Georgetown University Medical Center, 3900 Reservoir Road NW, Washington, DC 20007. Phone: (202) 687-1396; Fax: (202) 687-7186; E-mail: boularea{at}georgetown.edu Back

3 The abbreviations used are: VP-16, etoposide; PAR, poly(ADP-ribose); PARP-1, poly(ADP-ribose) polymerase-1; DFF, DNA fragmentation factor; BAPTA, 1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid; mut-PARP-1, PARP-1 mutant. Back

4 A. H. Boulares, A. J. Zoltoski, Z. A. Sherif, A. G. Yakovlev, and M. E. Smulson, unpublished observations. Back

Received 3/14/02. Accepted 5/31/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sellers W. R., Fisher D. E. Apoptosis and cancer drug targeting. J. Clin. Investig., 104: 1655-1661, 1999.[Medline]
  2. D’Arpa P., Liu L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989: 163-177, 1989.[Medline]
  3. Kawabata Y., Hirokawa M., Kitabayashi A., Horiuchi T., Kuroki J., Miura A. B. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: A novel mechanism of nuclear apoptosis resistance. Blood, 94: 3523-3530, 1999.[Abstract/Free Full Text]
  4. Zhang J., Wang X., Bove K. E., Xu M. DNA fragmentation factor 45-deficient cells are more resistant to apoptosis and exhibit different dying morphology than wild-type control cells. J. Biol. Chem., 274: 37450-37454, 1999.[Abstract/Free Full Text]
  5. Boulares A. H., Zoltoski A. J., Yakovlev A., Xu M., Smulson M. E. Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase in an amplification phase of tumor necrosis factor-induced apoptosis. J. Biol. Chem., 276: 38185-38192, 2001.[Abstract/Free Full Text]
  6. Robertson J. D., Orrenius S., Zhivotovsky B. Review: nuclear events in apoptosis. J. Struct. Biol., 129: 346-358, 2000.[Medline]
  7. Nagata S. Apoptotic DNA fragmentation. Exp. Cell Res., 256: 12-18, 2000.[Medline]
  8. Urbano A., McCaffrey R., Foss F. Isolation and characterization of NUC70, a cytoplasmic, hematopoietic apoptotic endonuclease. J. Biol. Chem., 273: 34820-34827, 1998.[Abstract/Free Full Text]
  9. Shiokawa D., Ohyama H., Yamada T., Takahashi K., Tanuma S. Identification of an endonuclease responsible for apoptosis in rat thymocytes. Eur. J. Biochem., 226: 23-30, 1994.[Medline]
  10. Los M., Neubuser D., Coy J. F., Mozoluk M., Poustka A., Schulze-Osthoff K. Functional characterization of DNase X, a novel endonuclease expressed in muscle cells. Biochemistry, 39: 7365-7373, 2000.[Medline]
  11. Liu X., Li P., Widlak P., Zou H., Luo X., Garrard W., Wang X. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc. Natl. Acad. Sci. USA, 95: 8461-8466, 1998.[Abstract/Free Full Text]
  12. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature (Lond.), 391: 43-50, 1998.[Medline]
  13. Liu X., Zou H., Slaughter C., Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell, 89: 175-184, 1997.[Medline]
  14. Yakovlev A. G., Wang G., Stoica B. A., Simbulan-Rosenthal C. M., Yoshihara K., Smulson M. E. Role of DNAS1L3 in Ca2+- and Mg2+-dependent cleavage of DNA into oligonucleosomal and high molecular mass fragments. Nucleic Acids Res., 27: 1999-2005, 1999.[Abstract/Free Full Text]
  15. Yakovlev A. G., Wang G., Stoica B. A., Boulares H. A., Spoonde A. Y., Yoshihara K., Smulson M. E. A role of the Ca2+/Mg2+-dependent endonuclease in apoptosis and its inhibition by Poly(ADP-ribose) polymerase. J. Biol. Chem., 275: 21302-21308, 2000.[Abstract/Free Full Text]
  16. Tanaka Y., Yoshihara K., Itaya A., Kamiya T., Koide S. S. Mechanism of the inhibition of Ca2+. Mg2+-dependent endonuclease of bull seminal plasma induced by ADP-ribosylation. J. Biol. Chem., 259: 6579-6585, 1984.[Abstract/Free Full Text]
  17. Boulares A. H., Zoltoski A. J., Contreras F. J., Yakovlev A. G., Yoshihara K., Smulson M. E. Regulation of DNAS1L3 endonuclease activity by poly(ADP-ribosyl)ation during etoposide-induced apoptosis. Role of poly(ADP-ribose) polymerase-1 cleavage in endonuclease activation. J. Biol. Chem., 277: 372-378, 2002.[Abstract/Free Full Text]
  18. Hashida T., Tanaka Y., Matsunami N., Yoshihara K., Kamiya T., Tanigawa Y., Koide S. S. Purification and properties of bull seminal plasma Ca2+. Mg2+-dependent endonuclease. J. Biol. Chem., 257: 13114-13119, 1982.[Free Full Text]
  19. Boulares H., Yakovlev A., Ivanova I., Stoica B. A., Wang G., Iyer S., Smulson M. E. Role of PARP cleavage in apoptosis: caspase 3 resistant PARP mutant increases rates of apoptosis in transfected cells. J. Biol. Chem., 274: 22932-22940, 1999.[Abstract/Free Full Text]
  20. Nicholson D. W., Ali A., Thornberry N. A., Vaillancourt J. P., Ding C. K., Gallant M., Gareau Y., Griffin P. R., Labelle M., Lazebnik Y. A., Munday N. A., Raju S. M., Smulson M. E., Yamin T. T., Yu V. L., Miller D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (Lond.), 376: 37-43, 1995.[Medline]
  21. Rosenthal D. S., Ding R., Simbulan-Rosenthal C. M., Vaillancourt J. P., Nicholson D. W., Smulson M. Intact cell evidence for the early synthesis, and subsequent late apopain-mediated suppression, of poly(ADP-ribose) during apoptosis. Exp. Cell Res., 232: 313-321, 1997.[Medline]
  22. Wong E., DeLuca C., Boily C., Charleson S., Cromlish W., Denis D., Kargman S., Kennedy B. P., Ouellet M., Skorey K., O’Neill G. P., Vickers P. J., Riendeau D. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm. Res., 46: 51-59, 1997.[Medline]
  23. Janicke R., ML. S., Wati M., Porter A. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 273: 9357-9360, 1998.[Abstract/Free Full Text]
  24. Tang D., Kidd V. J. Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis. J. Biol. Chem., 273: 28549-28552, 1998.[Abstract/Free Full Text]
  25. Boulares A. H., Zoltoski A. J., Sherif Z. A., Yakovlev A., Smulson M. E. Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase-1 in sensitization of fibroblasts to tumor necrosis factor-induced apoptosis. Biochem. Biophys. Res. Commun., 290: 796-801, 2002.[Medline]
  26. Zhang J., Lee H., Lou D. W., Bovin G. P., Xu M. Lack of obvious 50 kilobase pair DNA fragments in DNA fragmentation factor 45-deficient thymocytes upon activation of apoptosis. Biochem. Biophys. Res. Commun., 274: 225-229, 2000.[Medline]
  27. Sakahira H., Enari M., Ohsawa Y., Uchiyama Y., Nagata S. Apoptotic nuclear morphological change without DNA fragmentation. Curr. Biol., 9: 543-546, 1999.[Medline]
  28. Tamaoki T., Nomoto H., Takahashi I., Kato Y., Morimoto M., Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem. Biophys. Res. Commun., 135: 397-402, 1986.[Medline]
  29. Ruegg U. T., Burgess G. M. Staurosporine. K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci., 10: 218-220, 1989.[Medline]
  30. Herbert J. M., Seban E., Maffrand J. P. Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem. Biophys. Res. Commun., 171: 189-195, 1990.[Medline]
  31. Jacobson M. D., Burne J. F., King M. P., Miyashita T., Reed J. C., Raff M. C. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature (Lond.), 361: 365-369, 1993.[Medline]
  32. Jacobson M. D., Burne J. F., Raff M. C. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J., 13: 1899-1910, 1994.[Medline]
  33. Weil M., Jacobson M. D., Coles H. S., Davies T. J., Gardner R. L., Raff K. D., Raff M. C. Constitutive expression of the machinery for programmed cell death. J. Cell Biol., 133: 1053-1059, 1996.[Abstract/Free Full Text]
  34. Bertrand R., Solary E., O’Connor P., Kohn K. W., Pommier Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res., 211: 314-321, 1994.[Medline]
  35. Cai J., Jones D. P. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. J. Biol. Chem., 273: 11401-11404, 1998.[Abstract/Free Full Text]
  36. Kruman I., Guo Q., Mattson M. P. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J. Neurosci. Res., 51: 293-308, 1998.[Medline]
  37. Senturker S., Tschirret-Guth R., Morrow J., Levine R., Shacter E. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch. Biochem. Biophys., 397: 262-272, 2002.[Medline]
  38. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem. Pharmacol., 57: 231-245, 1999.[Medline]
  39. Duchen M. R. Mitochondria and calcium: from cell signaling to cell death. J. Physiol., 529 Pt 1: 57-68, 2000.[Abstract/Free Full Text]
  40. Yoshida A., Ueda T., Takauji R., Liu Y. P., Fukushima T., Inuzuka M., Nakamura T. Role of calcium ion in induction of apoptosis by etoposide in human leukemia HL-60 cells. Biochem. Biophys. Res. Commun., 196: 927-934, 1993.[Medline]
  41. Grant S., Turner A. J., Bartimole T. M., Nelms P. A., Joe V. C., Jarvis W. D. Modulation of 1-[ß-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncol. Res., 6: 87-99, 1994.[Medline]
  42. Sokolova I. A., Cowan K. H., Schneider E. Ca2+/Mg2+-dependent endonuclease activation is an early event in VP- 16-induced apoptosis of human breast cancer MCF7 cells in vitro. Biochim. Biophys. Acta, 1266: 135-142, 1995.[Medline]
  43. Bowman K. J., Newell D. R., Calvert A. H., Curtin N. J. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer, 84: 106-112, 2001.[Medline]
  44. Scovassi A. I., Mariani C., Negroni M., Negri C., Bertazzoni U. ADP-ribosylation of nonhistone proteins in HeLa cells: modification of DNA topoisomerase II. Exp. Cell Res., 206: 177-181, 1993.[Medline]
  45. Matikainen T., Perez G. I., Zheng T. S., Kluzak T. R., Rueda B. R., Flavell R. A., Tilly J. L. Caspase-3 gene knockout defines cell lineage specificity for programmed cell death signaling in the ovary. Endocrinology, 142: 2468-2480, 2001.[Abstract/Free Full Text]
  46. Kamesaki S., Kamesaki H., Jorgensen T. J., Tanizawa A., Pommier Y., Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res., 53: 4251-4256, 1993.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
J. Ehrchen, L. Steinmuller, K. Barczyk, K. Tenbrock, W. Nacken, M. Eisenacher, U. Nordhues, C. Sorg, C. Sunderkotter, and J. Roth
Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes
Blood, February 1, 2007; 109(3): 1265 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
J. A. Shaman, R. Prisztoka, and W. S. Ward
Topoisomerase IIB and an Extracellular Nuclease Interact to Digest Sperm DNA in an Apoptotic-Like Manner
Biol Reprod, November 1, 2006; 75(5): 741 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
L. A. Espinoza, F. Tenzin, A. O. Cecchi, Z. Chen, M. L. Witten, and M. E. Smulson
Expression of JP-8-Induced Inflammatory Genes in AEII Cells Is Mediated by NF-{kappa}B and PARP-1
Am. J. Respir. Cell Mol. Biol., October 1, 2006; 35(4): 479 - 487.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
B. Sotolongo, T. T. F. Huang, E. Isenberger, and W. S. Ward
An Endogenous Nuclease in Hamster, Mouse, and Human Spermatozoa Cleaves DNA into Loop-Sized Fragments
J Androl, March 1, 2005; 26(2): 272 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Zheng, K. Devalaraja-Narashimha, K. Singaravelu, and B. J. Padanilam
Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury
Am J Physiol Renal Physiol, February 1, 2005; 288(2): F387 - F398.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-P. Lee, D.-I. Tai, S.-L. Tsai, C.-T. Yeh, Y. Chao, S.-D. Lee, and M.-C. Hung
Adenovirus Type 5 E1A Sensitizes Hepatocellular Carcinoma Cells to Gemcitabine
Cancer Res., October 1, 2003; 63(19): 6229 - 6236.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Chen, N. Nguyen, K. Tamura, M. Karin, and R. H. Tukey
The Role of the Ah Receptor and p38 in Benzo[a]pyrene-7,8-dihydrodiol and Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced Apoptosis
J. Biol. Chem., May 23, 2003; 278(21): 19526 - 19533.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boulares, A. H.
Right arrow Articles by Smulson, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boulares, A. H.
Right arrow Articles by Smulson, M. E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online